ABL Texcell Diagnostics

ABL Texcell Diagnostics

EEURONEXT:ABLD
2.40
EUR
0.00
(0.00%)
44.70MMarket Cap
Mar 03Next Earn

Total Valuation

EUR

As of June 30, 2026, ABL Texcell Diagnostics carries a market capitalization of 44.70M, placing it among publicly traded companies globally. Its enterprise value stands at 45.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap44.70M
Enterprise Value45.66M

Important Dates

ABL Texcell Diagnostics's next confirmed earnings release is scheduled for March 3, 2027.

Earnings Date3/3/2027

Share Statistics

As of June 30, 2026, ABL Texcell Diagnostics has 16.08M shares outstanding.

Shares Outstanding16.08M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio6.30
P/TBV Ratio11.65

Financial Position

As of June 30, 2026, ABL Texcell Diagnostics maintains a current ratio of 2.26, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.

Current Ratio2.26
Quick Ratio0.21
Debt / Equity25.48

Financial Efficiency

These figures cover the twelve months ended June 30, 2026.

Employee Count21.00

Stock Price Statistics

EUR

As of the close on November 17, 2026, ABL Texcell Diagnostics's stock has declined approximately 17.24% over the past 52 weeks. The 50-day moving average sits at 2.38, while the 200-day moving average is 2.74.

52-Week Price Change-17.24%
50-Day Moving Average2.38
200-Day Moving Average2.74

Balance Sheet

EUR

As of June 30, 2026, ABL Texcell Diagnostics holds 853,726.00 in cash and equivalents against 1.81M in total debt, resulting in a net debt position of 1.12M. Total book value stands at 7.10M, with working capital of 5.10M providing operational flexibility.

Cash & Cash Equivalents853,726.00
Total Debt1.81M
Net Debt1.12M
Equity (Book Value)7.10M
Book Value Per Share0.44
Working Capital5.10M

Stock Splits

ABL Texcell Diagnostics's most recent stock split took place on May 18, 2022 with a 1:8 split ratio.

Last Split Date5/18/2022
Split Ratio1:8